Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesRepligen Corporation

Repligen Corporation

Healthcare Medical Instruments & Supplies
PortfolioPortfolio WatchlistWatchlist
Company price
175.29 USD 1.80 ( 1.04%)
Last update at 2026-11-09T17:47:00Z
VOLUME
285137
Market Cap
9861.00M
P/E
242.68

Momentum Score

…

Repligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally. The company's products include hollow fiber consumables, KRM chromatography system, resins for new modalities, PATsmart MAVERICK and PATsmart MAVEN for real-time monitoring and control of critical bioprocess parameters, PATsmart REBEL, an at-line cell culture media analyzer; and PATsmart ZipChip, a high-resolution sample separations device, PATsmart SoloVPE slope spectroscopy system, and SoloVPE PLUS System. It offers Protien A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company also provides chromatography products, including OPUS pre-packed chromatography columns, which are used in the purification and quality control of biological drugs, as well as ELISA test kits. In addition, it offers filtration products, such as XCell ATF Cell Retention Systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems. The company offers its products under the OPUS, XCell, XCell ATF, TFDF, KrosFlo, SIUS, ProConnex, Spectra/Por, NGL-Impact, SoloVPE, FlowVPE, RPM, XO, Metenova MixOne, and AVIPure and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has a collaboration agreement with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
172.39
Low
177.46
High
52 Week Price Range
100.99
Low
188.73
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Repligen supplies consumables and process technologies for development and manufacture of biologic drugs, including chromatography media, single-use systems and filtration products for biopharma and contract manufacturers. Long-term growth may come from rising demand for monoclonal antibodies and cell therapies, greater outsourcing to CDMOs and recurring sales of disposable consumables as production scales.

Material risks include strong competition from larger life-science suppliers, customer concentration and lengthy product qualification cycles, plus sensitivity to biomanufacturing capital-spending swings and supply-chain disruption.

Risk Score
Medium

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
173.49
Dividend Yield
-
Revenue TTM
785.10M
Revenue Per Share
13.94
Gross Profit TTM
422.67M
Debt / Equity
0.33
ROE
1.99%
Net Debt
123.93M
ROCE
3.04%
Diluted EPS TTM
0.72

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax 62.38M -27.04M 64.13M 219.14M 153.54M
Net income 48.89M -25.51M 41.58M 185.96M 128.29M
Selling general administrative 290.51M 263.37M 213.84M 215.83M 183.87M
Gross profit 347.62M 274.64M 284.25M 455.71M 391.25M
Reconciled depreciation 96.96M 86.56M 65.32M 50.98M 38.45M
Ebit 85.56M -6.30M 56.21M 133.61M 133.50M
Ebitda 164.30M 80.26M 124.29M 184.59M 171.95M
Depreciation and amortization 78.75M 86.56M 68.08M 50.98M 38.45M
Non operating income net other - - - -4.37M -0.99M
Operating income 59.58M -35.11M 54.58M 133.61M 133.50M
Other operating expenses 678.68M 669.55M 584.19M 605.60M 497.42M
Interest expense 23.17M 22.57M 10.03M 1.16M 12.71M
Tax provision 13.49M -1.52M 10.08M 33.18M 25.25M
Net interest income -23.17M -22.57M -2.91M -2.98M -12.71M
Income tax expense 13.49M -1.52M 22.55M 33.18M 25.25M
Total revenue 738.26M 634.44M 638.76M 801.54M 670.53M
Total operating expenses 288.05M 309.76M 230.27M 259.76M 218.14M
Cost of revenue 390.63M 359.79M 354.52M 345.83M 279.28M
Total other income expense net 2.81M 8.08M 9.56M 85.53M 20.04M
Net income from continuing ops 48.89M -25.51M 115.79M 185.96M 128.29M
Net income applicable to common shares - - - 185.96M 128.29M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 2949.70M 2829.67M 2824.41M 2524.66M 2358.35M
Intangible assets 386.15M 397.90M 400.49M 353.68M 337.27M
Other current assets 40.71M 31.61M 33.24M 17.41M 19.27M
Total liab 843.57M 856.95M 853.21M 613.96M 608.29M
Total stockholder equity 2106.13M 1972.72M 1971.20M 397.27M 1750.07M
Deferred long term liab - - - 23.00M 33.48M
Other current liab 69.65M 66.31M 53.23M 65.79M 60.65M
Common stock 0.56M 0.56M 0.56M 0.56M 0.55M
Capital stock 0.56M 0.56M 0.56M 0.56M 0.55M
Retained earnings 456.25M 407.35M 438.85M 397.27M 194.06M
Other liab - - - 78.37M 130.53M
Good will 1114.41M 1030.99M 987.12M 855.51M 860.36M
Other assets - 282.08M - 1.66M 2.52M
Cash 566.02M 757.36M 751.32M 523.46M 603.81M
Total current liabilities 135.83M 126.79M 158.16M 404.20M 375.26M
Current deferred revenue 14.61M 13.24M 10.29M 19.28M 14.85M
Net debt 123.93M -71.11M -39.52M -100.50M -237.76M
Short term debt 21.56M 15.10M 75.08M 291.57M 263.56M
Short long term debt - - 69.45M 284.62M 255.26M
Short long term debt total 689.95M 686.25M 711.80M 422.96M 366.05M
Other stockholder equity 1651.85M 1617.34M 1569.23M 33.84M 1572.34M
Property plant equipment - - - 190.67M 124.96M
Total current assets 1137.38M 1066.04M 1111.04M 998.12M 931.68M
Net tangible assets - - - 701.51M 552.43M
Short term investments 201.61M 26.61M 0.00M 100.30M -
Net receivables 158.59M 134.12M 124.16M 116.25M 117.42M
Long term debt 542.21M 525.57M 510.14M - -
Inventory 170.46M 142.96M 202.32M 238.28M 184.49M
Accounts payable 30.01M 32.13M 19.56M 27.55M 36.20M
Accumulated other comprehensive income -2.53M -52.53M -37.43M -34.39M -16.89M
Common stock total equity - - - 0.56M 0.55M
Retained earnings total equity - - - 397.27M 194.06M
Non currrent assets other 4.91M 0.87M 1.28M 0.81M 0.61M
Non current assets total 1812.31M 1763.62M 1713.37M 1526.54M 1426.68M
Capital lease obligations 147.74M 160.68M 132.21M 138.35M 110.80M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments -200.26M -86.38M -74.68M -100.00M -221.17M
Change to liabilities - - - -9.25M 41.30M
Total cashflows from investing activities -298.47M -86.38M - -233.24M -221.17M
Net borrowings 0.00M -69.94M - -0.03M -0.02M
Total cash from financing activities -15.21M -82.90M 248.96M -13.34M 0.96M
Change to operating activities - - - 5.19M 14.65M
Net income 48.89M -25.51M 41.58M 185.96M 128.29M
Change in cash -191.33M 6.03M 227.87M -80.36M -113.48M
Begin period cash flow 757.36M 751.32M 523.46M 603.81M 717.29M
End period cash flow 566.02M 757.36M 751.32M 523.46M 603.81M
Total cash from operating activities 117.42M 175.39M 113.92M 172.08M 119.02M
Issuance of capital stock - - - 0.00M 0.00M
Depreciation 96.96M 86.56M 68.08M 50.98M 38.45M
Other cashflows from investing activities -4.37M -5.94M - -48.40M -154.08M
Dividends paid - - 565.68M 17.02M 2.90M
Change to inventory -14.95M 56.90M 40.97M -57.20M -89.78M
Change to account receivables -17.16M -14.03M -3.31M -3.60M -46.52M
Sale purchase of stock 0.00M -14.39M -14.39M -17.02M -2.90M
Other cashflows from financing activities -18.38M -17.26M -20.57M 17.02M -76.19M
Change to netincome - - - 25.86M 34.88M
Capital expenditures 23.52M 32.91M 38.99M 133.35M 71.28M
Change receivables - - - -3.60M -46.52M
Cash flows other operating - - - -22.49M 0.88M
Exchange rate changes - - - - -12.29M
Cash and cash equivalents changes - - - -74.49M -113.48M
Change in working capital -50.88M 60.92M -8.64M -63.81M -102.13M
Stock based compensation 32.60M 48.07M 25.57M 27.32M 27.50M
Other non cash items -6.79M 22.14M -15.00M -27.01M 20.39M
Free cash flow 93.90M 142.49M 74.93M 38.74M 47.74M

Peer Comparison*

Sector: Healthcare Industry: Medical Instruments & Supplies

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
RGEN
Repligen Corporation		 1.80
1.04%		 175.29 242.68 61.35 12.56 4.49 11.92 54.55
ISRG
Intuitive Surgical Inc		 8.91
1.97%		 461.71 43.30 31.35 12.25 7.35 11.63 30.22
ESLOF
EssilorLuxottica Société anonyme		 0.74
0.35%		 213.60 44.84 27.62 4.07 2.49 3.71 16.04
ESLOY
Essilor International SA		 -0.81
0.75%		 106.94 41.68 27.25 3.94 2.45 3.71 16.04
BDX
Becton Dickinson and Company		 3.97
1.87%		 215.85 31.62 13.76 2.25 2.04 2.93 13.40

Profile*

Repligen Corporation

Repligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally. The company's products include hollow fiber consumables, KRM chromatography system, resins for new modalities, PATsmart MAVERICK and PATsmart MAVEN for real-time monitoring and control of critical bioprocess parameters, PATsmart REBEL, an at-line cell culture media analyzer; and PATsmart ZipChip, a high-resolution sample separations device, PATsmart SoloVPE slope spectroscopy system, and SoloVPE PLUS System. It offers Protien A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company also provides chromatography products, including OPUS pre-packed chromatography columns, which are used in the purification and quality control of biological drugs, as well as ELISA test kits. In addition, it offers filtration products, such as XCell ATF Cell Retention Systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems. The company offers its products under the OPUS, XCell, XCell ATF, TFDF, KrosFlo, SIUS, ProConnex, Spectra/Por, NGL-Impact, SoloVPE, FlowVPE, RPM, XO, Metenova MixOne, and AVIPure and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has a collaboration agreement with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts.

Building 1, Waltham, MA, United States, 02453

781 250 0111

https://www.repligen.com

2000

Name Title Year Born
Mr. Anthony J. Hunt Pres, CEO & Director 1964
Mr. Jon K. Snodgres Chief Financial Officer 1966
Mr. James R. Bylund Chief Operating Officer 1964
Ms. Christine Gebski Sr. VP of Filtration & Chromatography 1969
Mr. Ralf Kuriyel Sr. VP of R&D 1959
Ms. Sondra S. Newman Global Head of Investor Relations NA
Ms. Kimberly Cornwell Global Head of Legal & Gen. Counsel NA
Mr. Stephen Tingley VP & Head of Global Sales NA
Ms. Rachel Goodrich VP of Marketing NA
Mr. Craig Harrison Sr. VP of Process Analytics NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

GFR
CAD 10.94
+37.96%
MOON
CAD 4.90
+11.11%
UCU
CAD 2.37
+10.75%
ANRG
CAD 1.90
+10.47%
EPRX
CAD 10.71
+10.30%
DIV
CAD 3.77
-7.37%
CSU
CAD 3281.97
-6.93%
LMN
CAD 26.62
-5.23%
TOI
CAD 99.75
-4.80%
GRZ
CAD 5.05
-4.72%

Equity Sectors*

  • Basic Materials

    +4.21%

  • Communication Services

    -0.63%

  • Consumer Cyclical

    +1.12%

  • Consumer Defensive

    +0.09%

  • Energy

    +1.91%

  • Financial Services

    +1.63%

  • Healthcare

    +1.49%

  • Industrials

    +3.56%

  • Real Estate

    +0.66%

  • Technology

    +1.84%

  • Utilities

    +1.24%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…